The University of Manchester Division of Psychology and Mental Health, Manchester, UK
Institute of Population Health, University of Liverpool, Liverpool, UK, Liverpool, UK.
BMJ Open. 2024 Oct 23;14(10):e090290. doi: 10.1136/bmjopen-2024-090290.
Schizophrenia and attention deficit hyperactivity disorder (ADHD) are psychiatric disorders that have a profound impact on patients and healthcare systems globally. There is preliminary evidence suggesting a potential association between the two in terms of symptomatology and genetic underpinning. There is a paucity of guidance regarding pharmacological approaches for patients with comorbid ADHD and schizophrenia. There is a concern that psychostimulants may be more harmful than therapeutic. This scoping review protocol aims to systematically review the evidence for potential harm and benefit of psychostimulants among patients with comorbid ADHD and schizophrenia and identify research gaps.
This scoping review will employ a systematic and iterative approach to identify and synthesise the literature on the topic of psychostimulant use among patients with comorbid schizophrenia and ADHD, based on Arksey and O'Malley's framework. A search will be conducted in relevant databases, including MEDLINE (Ovid), Embase (Ovid), PsycINFO and ISI Web of Science. Additionally, grey literature will be sought. The scoping review will involve two independent reviewers screening the search results. The initial screen will be of title and abstract, and the subsequent full-text review will determine eligibility. A descriptive overview of the eligible studies will be provided. This scoping review has been registered at https://osf.io/cmn5s.
There is a paucity of high-quality evidence available to clinicians when making decisions regarding the prescription of psychostimulants to patients with comorbid schizophrenia and ADHD. To the best of our knowledge, this will be the first scoping review to examine the evidence addressing this clinical scenario. This review, therefore, has the potential to contribute to decision-making processes for this patient group, thereby improving patient outcomes. Furthermore, as this review is designed to identify research gaps, we aim to contribute to the development of a research agenda that will benefit patients, clinicians and healthcare systems. The dissemination strategy will involve open access peer review publication and scientific presentations.
精神分裂症和注意缺陷多动障碍（ADHD）是两种对全球患者和医疗体系都有深远影响的精神疾病。有初步证据表明，这两种疾病在症状和遗传基础方面可能存在关联。对于同时患有 ADHD 和精神分裂症的患者，药物治疗方法的相关指导非常有限。人们担心使用精神兴奋剂可能弊大于利。本研究旨在系统回顾精神兴奋剂在同时患有 ADHD 和精神分裂症的患者中的潜在危害和益处的证据，并确定研究空白。
本研究将采用系统和迭代的方法，根据 Arksey 和 O'Malley 的框架，在相关数据库中（包括 Ovid 中的 MEDLINE、Ovid 中的 Embase、PsycINFO 和 ISI Web of Science）检索和综合关于精神兴奋剂在同时患有精神分裂症和 ADHD 的患者中使用的文献。此外，还将寻找灰色文献。这项范围综述将涉及两名独立的审查员筛选检索结果。最初筛选将是标题和摘要，然后进行全文审查以确定合格性。将提供合格研究的描述性概述。本范围综述已在 https://osf.io/cmn5s 上注册。
当涉及为同时患有精神分裂症和 ADHD 的患者开处精神兴奋剂处方时，临床医生可获得的高质量证据有限。据我们所知，这将是第一项审查该临床情况证据的范围综述。因此，该综述有可能为该患者群体的决策过程做出贡献，从而改善患者的预后。此外，由于本综述旨在确定研究空白，我们旨在为有助于患者、临床医生和医疗体系的研究议程的制定做出贡献。传播策略将包括同行评审的开放获取发表和科学报告。
